Jeremy Bastid, Chief Development Officer at ORPHELIA Pharma will attend the SIOPEN annual general meeting. The SIOPEN annual meeting brings together about 200 clinicians, investigators, researchers and patient advocates from 34 European countries to discuss on-going clinical trials, results, and work in progress in the field of neuroblastoma.
initiative Octalfa
Engagés pour l'innovation et la santé
